PHR1027
Guaifenesin
certified reference material, pharmaceutical secondary standard
Synonym(s):
Guaiacol glyceryl ether, 3-(o-Methoxyphenoxy)-1,2-propanediol, Glycerol guaiacolate, Guaifenesin
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C10H14O4
CAS Number:
Molecular Weight:
198.22
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
certified reference material
pharmaceutical secondary standard
Quality Level
Agency
traceable to Ph. Eur. G0700000
traceable to USP 1301007
API family
guaifenesin
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
SMILES string
COc1ccccc1OCC(O)CO
InChI
1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3
InChI key
HSRJKNPTNIJEKV-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
Guaifenesin is an expectorant, widely used in the treatment of cough. Its mode of action involves the alleviating of cough discomfort by increasing sputum volume and decreasing its viscosity, thus resulting in effective cough.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Application
Guaifenesin may be used as a reference standard in determining the concentration of guaifenesin present in pharmaceutical formulations and human plasma using colorimetric technique and high performance liquid chromatography (HPLC), respectively. It may also be used pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using reversed-phase high-performance liquid chromatography technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Analysis Note
These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Footnote
To see an example of a Certificate of Analysis for this material enter LRAC3180 in the slot below. This is an example certificate only and may not be the lot that you receive.
related product
Product No.
Description
Pricing
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Development and validation of stability indicating the RP-HPLC method for the estimation of related compounds of guaifenesin in pharmaceutical dosage forms
Reddy PS, et al.
Pharmaceutical Methods, 2(4), 229-234 (2011)
Development and validation of a high-performance liquid chromatographic method for the determination of methocarbamol in human plasma
Naidong W, et al.
Journal of Chromatography. B, Biomedical Applications, 287-292 (1994)
Sensitive spectrophotometric method for quantitation of guaifenesin and dropropizine in their dosage forms
Abdallah.MO, et al.
International Journal of Analytical Chemistry (2010)
Robert J Brosnan et al.
American journal of veterinary research, 72(12), 1569-1575 (2011-12-01)
To evaluate whether guaifenesin can prevent adverse anesthetic induction events caused by propofol and whether a guaifenesin-propofol induction combination has brief cardiovascular effects commensurate with rapid drug washout. 8 healthy adult horses. Guaifenesin was administered IV for 3 minutes followed
Mallinath B Hadimani et al.
Journal of medicinal chemistry, 56(12), 5071-5078 (2013-06-14)
In diabetic patients, an early index of peripheral neuropathy is the slowing of conduction velocity in large myelinated neurons and a lack of understanding of the basic pathogenic mechanisms hindered therapeutics development. Racemic (R/S)-guaifenesin (1) was identified as a potent
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service